On Monday, William Blair adjusted its stance on Amedisys (NASDAQ:AMED) stock, shifting the rating from Outperform to Market Perform. The move comes after developments in the company's ongoing acquisition process by United Health Group . Amedisys had been anticipated to sell off some of its home health assets to address antitrust issues related to the merger.
The divestiture process, involving over 100 Amedisys locations, is advancing as planned, with Vital Caring identified as the potential buyer. Although the final purchase price and the exact number of locations involved in the sale have not been disclosed, the agreement is seen as a key step towards finalizing the United Health-Amedisys transaction.
The firm's decision to downgrade the stock follows the release of the 2025 home health rule proposal by the Centers for Medicare & Medicaid Services (CMS) just a day prior to the divestiture news. Analysts at William Blair consider the timing of these events to be non-coincidental and indicative of a strategic alignment with regulatory expectations.
With the divestiture agreement in place, the perceived risk of the deal not concluding has been significantly reduced. This is reflected in the aftermarket stock price, which rose to approximately $96.
The current price suggests a narrower spread, around 5%, which is a tighter margin than seen in recent months when investor concerns regarding the deal's closure were more pronounced.
The updated stock rating to Market Perform reflects the analyst's view that the stock price now more accurately represents the likelihood of the acquisition's successful completion within the second half of 2024, as previously stated by Amedisys and United Health Group.
In other recent news, Amedisys Inc ., a prominent home health care services provider, has announced a definitive agreement for the sale of certain home health care centers to VCG Luna, LLC, an affiliate of VitalCaring Group. This transaction is a strategic divestiture in anticipation of a merger with UnitedHealth Group (NYSE:UNH).
The sale includes specific Amedisys home health locations and select UnitedHealth Group care centers, with the divestiture being viewed as a significant step towards fulfilling the conditions necessary for the merger's completion.
The merger, anticipated to be finalized in the second half of 2024, will see Amedisys becoming a wholly owned subsidiary of UnitedHealth Group. The completion of the divestiture is contingent on the closing of the merger between Amedisys and UnitedHealth Group's subsidiary, Aurora Holdings Merger Sub Inc. This strategic move is subject to customary closing conditions and regulatory approvals.
These recent developments underscore the ongoing consolidation in the healthcare industry, with companies aiming to enhance capabilities in providing integrated healthcare services.
Both Amedisys and UnitedHealth Group have expressed commitment to ensuring a smooth transition for the affected centers, with a focus on maintaining high-quality care for patients and continuity of services.
InvestingPro Insights
In the light of recent developments with Amedisys (NASDAQ:AMED), including the ongoing acquisition process and the divestiture of home health assets, it's valuable to consider key financial metrics and analyst insights. According to InvestingPro data, Amedisys has a market capitalization of $3 billion, with a forward-looking P/E ratio for the last twelve months as of Q1 2024 at 29.32, which suggests expectations of profitability in the near future. This aligns with an InvestingPro Tip that analysts predict the company will be profitable this year.
The revenue growth for the last twelve months as of Q1 2024 stood modest at 0.76%, with a more pronounced quarterly revenue growth rate of 2.7% for Q1 2024. Additionally, the company's gross profit margin remains strong at 44.39%, indicating a solid ability to control costs relative to revenue. Another InvestingPro Tip to consider is that five analysts have revised their earnings upwards for the upcoming period, which may signal confidence in the company's financial performance moving forward.
Investors looking for further insights into Amedisys can find additional tips on InvestingPro, taking advantage of the coupon code PRONEWS24 for an extra 10% off a yearly or biyearly Pro and Pro+ subscription. With more tips available, investors can gain a comprehensive understanding of the company's potential and make informed decisions in the context of the current healthcare industry dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.